KR20240111752A - Rna에 작용하는 내인성 아데노신 데아미나아제(adar)에 의한 효율적이고 정확한 rna 편집을 위한 안티센스 올리고뉴클레오티드(aso) - Google Patents

Rna에 작용하는 내인성 아데노신 데아미나아제(adar)에 의한 효율적이고 정확한 rna 편집을 위한 안티센스 올리고뉴클레오티드(aso) Download PDF

Info

Publication number
KR20240111752A
KR20240111752A KR1020247016720A KR20247016720A KR20240111752A KR 20240111752 A KR20240111752 A KR 20240111752A KR 1020247016720 A KR1020247016720 A KR 1020247016720A KR 20247016720 A KR20247016720 A KR 20247016720A KR 20240111752 A KR20240111752 A KR 20240111752A
Authority
KR
South Korea
Prior art keywords
chemically modified
modified oligonucleotide
editing
oligonucleotide
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016720A
Other languages
English (en)
Korean (ko)
Inventor
토르슈텐 슈타포르스트
은가드님 라티피
라우라 조피아 파이퍼
Original Assignee
에버하르트-칼스 유니버시태트 튀빙겐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에버하르트-칼스 유니버시태트 튀빙겐 filed Critical 에버하르트-칼스 유니버시태트 튀빙겐
Publication of KR20240111752A publication Critical patent/KR20240111752A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247016720A 2021-11-30 2022-11-29 Rna에 작용하는 내인성 아데노신 데아미나아제(adar)에 의한 효율적이고 정확한 rna 편집을 위한 안티센스 올리고뉴클레오티드(aso) Pending KR20240111752A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21211372.4 2021-11-30
EP21211372 2021-11-30
PCT/EP2022/083711 WO2023099494A1 (en) 2021-11-30 2022-11-29 Antisense oligonucleotides (aso) for efficient and precise rna editing with endogenous adenosine deaminase acting on rna (adar)

Publications (1)

Publication Number Publication Date
KR20240111752A true KR20240111752A (ko) 2024-07-17

Family

ID=78820190

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016720A Pending KR20240111752A (ko) 2021-11-30 2022-11-29 Rna에 작용하는 내인성 아데노신 데아미나아제(adar)에 의한 효율적이고 정확한 rna 편집을 위한 안티센스 올리고뉴클레오티드(aso)

Country Status (9)

Country Link
US (1) US20230235329A1 (https=)
EP (1) EP4441216A1 (https=)
JP (1) JP2024544067A (https=)
KR (1) KR20240111752A (https=)
CN (1) CN118355119A (https=)
AU (1) AU2022399905A1 (https=)
CA (1) CA3238033A1 (https=)
IL (1) IL312762A (https=)
WO (1) WO2023099494A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024114908A1 (en) * 2022-11-30 2024-06-06 Eberhard Karls Universität Tübingen Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
AU2024325709A1 (en) * 2023-08-15 2026-01-29 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
WO2025073902A1 (en) * 2023-10-06 2025-04-10 Eberhard Karls Universität Tübingen Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing
WO2025172372A1 (en) 2024-02-12 2025-08-21 Airna Corporation Conjugate for targeted delivery of an antisense oligonucleotide
WO2025242018A1 (zh) * 2024-05-20 2025-11-27 时夕(广州)生物科技有限公司 一种经修饰的向导agRNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10941402B2 (en) 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
WO2020001793A1 (en) 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
CA3158528A1 (en) * 2019-12-23 2021-07-01 Jim SWILDENS Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease

Also Published As

Publication number Publication date
IL312762A (en) 2024-07-01
JP2024544067A (ja) 2024-11-27
US20230235329A1 (en) 2023-07-27
WO2023099494A1 (en) 2023-06-08
CA3238033A1 (en) 2023-06-08
AU2022399905A1 (en) 2024-05-23
WO2023099494A9 (en) 2024-10-17
EP4441216A1 (en) 2024-10-09
CN118355119A (zh) 2024-07-16

Similar Documents

Publication Publication Date Title
CN113994000B (zh) 包括胞苷类似物的反义rna编辑寡核苷酸
KR20240111752A (ko) Rna에 작용하는 내인성 아데노신 데아미나아제(adar)에 의한 효율적이고 정확한 rna 편집을 위한 안티센스 올리고뉴클레오티드(aso)
KR20240016350A (ko) Rna에 작용하는 내인성 아데노신 데아미나아제(adar)에 의한 효율적이고 정확한 rna 편집을 위한 안티센스 올리고뉴클레오티드(aso)
CN114514318A (zh) 寡核苷酸和靶rna的位点特异性编辑方法
AU2020223440A1 (en) Antisense oligonucleotides for nucleic acid editing
AU2024247459A1 (en) Chemically modified antisense oligonucleotides for use in rna editing
TW202020152A (zh) 調節rtel1表現之寡核苷酸
KR20250109237A (ko) Rna 편집을 위한 화학적으로 변형된 안티센스 올리고뉴클레오티드(aso) 및 이를 포함하는 조성물
TW202329983A (zh) Ｒｎａ編輯
CN114867856A (zh) Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
EP3628737A1 (en) Ena antisense oligonucleotide for inhibition of alpha-synuclein expression
JP2025528464A (ja) トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
CN120476207A (zh) 反义寡核苷酸治疗遗传性hfe血色素沉着症
JP2021502059A (ja) 部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
CN114829601A (zh) Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
KR20240110595A (ko) 안정화된 rna 제제
KR20260053296A (ko) Rna 편집을 위한 화학적으로 변형된 안티센스 올리고뉴클레오티드(asos) 및 조성물
HK40110334A (zh) Rna编辑
JP2021193905A (ja) 育毛を促進するための組成物
HK40077333A (en) Use of saraf inhibitors for treating hepatitis b virus infection
KR20210041537A (ko) 포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
KR20190062290A (ko) 이중 가닥의 올리고뉴클레오티드 및 그 제조 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000